Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.51 |
| ▸ | GUCY1A1 | Q02108 | 17/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 17/20 | 0.49 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.41 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783451 | 0.91 | GUCY1A1 (0.61) | KEAP1NFE2L2GUCY1A1GUCY1B1 | |
| SCHEMBL18335055 | 0.89 | GUCY1A1 (0.43) | KEAP1NFE2L2GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL1781395 | 0.84 | GUCY1A1 (0.61) | KEAP1NFE2L2GUCY1A1GUCY1B1 | |
| SCHEMBL3997084 | 0.82 | KEAP1 (0.47) | KEAP1NFE2L2GUCY1A1GUCY1B1 | |
| SCHEMBL4002464 | 0.82 | KEAP1 (0.47) | KEAP1NFE2L2GUCY1A1GUCY1B1 | |
| SCHEMBL12603865 | 0.82 | KEAP1 (0.50) | KEAP1NFE2L2GUCY1A1GUCY1B1 | |
| SCHEMBL3997178 | 0.81 | KEAP1 (0.51) | KEAP1NFE2L2GUCY1A1GUCY1B1 | |
| SCHEMBL12603868 | 0.81 | KEAP1 (0.49) | KEAP1NFE2L2GUCY1A1GUCY1B1 | |
| SCHEMBL3998243 | 0.81 | KEAP1 (0.49) | KEAP1NFE2L2GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL14952921 | 0.80 | KEAP1 (0.50) | KEAP1NFE2L2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | claimed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | claimed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | claimed |
| EP-2197551-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2010-06-23 | — | — | EP | claimed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | claimed |
| WO-2009032249-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK & CO., INC. (US) | 2009-03-12 | — | — | WO | claimed |
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015095515-A1 | SGC ACTIVATORS FOR THE TREATMENT OF GLAUCOMA | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| EP-2197551-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2010-06-23 | — | — | EP | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2009032249-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK & CO., INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | KEAP1 2477/4885NFE2L2 2819/4885GUCY1A1 3/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | KEAP1 2477/4885NFE2L2 2819/4885GUCY1A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.